[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363594-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363594-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","disease-status-stratification-individualizes-radioiodine-therapy-for-differentiated-thyroid-cancer-a-prospective-multicenter-real-world-study","Disease status stratification individualizes radioiodine therapy for differentiated thyroid cancer - a prospective, multicenter, real-world study","","Recurrence risk stratification systems guiding 131I therapy for differentiated thyroid cancer face feasibility and justification challenges. A prospective, multicenter, real-world study consecutively labeled patients without evidence of disease, unexplained hyperthyroglobulinemia, or known disease using stimulated thyroglobulin, radioiodine uptake, and imaging, then allocated them to RRA, RAT, or ROT. Primary outcomes were DFS for RRA/RAT and PFS/OS for ROT, showing 5-year survival and response rates supporting individualized 131I guidance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/disease-status-stratification-individualizes-radioiodine-therapy-for-differentiated-thyroid-cancer-a-prospective-multicenter-real-world-study/363594/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/disease-status-stratification-individualizes-radioiodine-therapy-for-differentiated-thyroid-cancer-a-prospective-multicenter-real-world-study/363594.png","ImageObject",300,407,{"name":42,"@type":43},"Jasmine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were patients classified for different 131I treatment strategies?","Question",{"text":63,"@type":64},"Patients were consecutively labeled as having no evidence of disease, unexplained hyperthyroglobulinemia, or known disease based on stimulated serum thyroglobulin, radioiodine uptake, and medical imaging.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the primary endpoints for each treatment group?",{"text":68,"@type":64},"DFS was the primary endpoint for the RRA and RAT groups, while PFS and OS were primary endpoints for the ROT group.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes did the study report for 5-year DFS, PFS, and OS?",{"text":72,"@type":64},"The 5-year DFS rates were 93.28% (RRA) and 76.02% (RAT). For ROT, the 5-year PFS and OS rates were 72.23% and 99.01%, respectively.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363594,1790293112,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Qiu etal. BMC Cancer (2026) 26:719 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16030-1](https://doi.org/10.1186/s12885-026-16030-1)  \nRESEARCH Open Access  \nDisease status stratification individualizes   radioiodine therapy for differentiated thyroid cancer: a prospective, multicenter, real-world study  \nXian Qiu1†, Lin Cheng1†, Yuchen Jin1, Hao Fu1,2, Ri Sa1,3, Ziyan He1, Qiong Luo4, Linglin Tang5, Yi Yang6, Chunjing Yu7 and Libo Chen1*  \nAbstract  \nBackground Recurrence risk stratification system-guided radioiodine ( 131 I) therapy of differentiated thyroid cancer (DTC) has fallen into dilemma due to its poor feasibility and insufficient justification.  \nMethods Subjects referred for 131 I therapy were consecutively labeled with no evidence of disease, unexplained hyperthyroglobulinemia, or known disease based on stimulated serum thyroglobulin, radioiodine uptake, and medical imaging, and then assigned to radioiodine remnant ablation (RRA), radioiodine adjuvant treatment (RAT), or radioiodine oncolytic treatment (ROT) group, respectively. The primary endpoints were disease-free survival (DFS) for the RRA and RAT cohorts and progression-free survival (PFS) and overall survival (OS) for the ROT cohort. Secondary endpoints included success rate in the RRA cohort, response classification in all cohorts, and biochemical and structural responses in the ROT cohort.  \nResults In the RRA and RAT cohorts, the 5-year DFS rates were 93. 28% and 76. 02%, respectively. In the ROT cohort, the 5-year PFS and OS rates were 72. 23% and 99. 01%, respectively. In the RRA cohort, an 85. 06% success rate was achieved, with excellent response (ER), indeterminate response (IR), biochemical incomplete response (BIR) and structural/functional incomplete response (S/FIR) rates of 77 . 92%, 15. 58%, 3 . 9%, and 2. 6%, respectively. In RAT cohort, ER, IR, BIR and S/FIR rates were 16.42%, 26 . 87%, 33 . 83%, and 22. 89%, respectively. In the ROT cohort, ER, IR, BIR, and S/ FIR rates were 2 . 5%, 3 . 33%, 8 . 33%, and 85. 83%, respectively, with biochemical remission rate of 69 .49% and structural disease control rate of 96. 15% .  \nConclusion This prospective, multicenter, real-world study justified postoperative disease status stratification as a feasible guidance for individualizing 131 I therapy of DTC.  \nKeywords Differentiated thyroid cancer, Disease status stratification, Radioiodine, Thyroglobulin, Personalized care  \n†Xian Qiu and Lin Cheng were co-first authors.  \n*Correspondence: Libo Chen [lbchen@sjtu.edu.cn](lbchen@sjtu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nQiu et al. BMC Cancer (2026) 26:719  \nIntroduction  \nThyroid cancer is among the most common malignancies with a steadily and rapidly increasing global incidence. In 2020, there were approximately 586,000 new cases w","cbCailA4aamXIQsm","https://ap.wps.com/l/cbCailA4aamXIQsm","pdf",4227971,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"How were patients classified for different 131I treatment strategies?\",\"answer\":\"Patients were consecutively labeled as having no evidence of disease, unexplained hyperthyroglobulinemia, or known disease based on stimulated serum thyroglobulin, radioiodine uptake, and medical imaging.\"},{\"question\":\"What were the primary endpoints for each treatment group?\",\"answer\":\"DFS was the primary endpoint for the RRA and RAT groups, while PFS and OS were primary endpoints for the ROT group.\"},{\"question\":\"What outcomes did the study report for 5-year DFS, PFS, and OS?\",\"answer\":\"The 5-year DFS rates were 93.28% (RRA) and 76.02% (RAT). For ROT, the 5-year PFS and OS rates were 72.23% and 99.01%, respectively.\"}]","Disease status stratification individualizes radioiodine therapy for differentiated thyroid cancer - a prospective, multicenter, real-world study | PDF",1790152023,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8001c87871ebeff5a5484f31897d9b92.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21afb3fcec0f5e4ca55da81b27bf4c03.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32e04ad275e002b237f5e541d2ed52b5.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7be21724726e700be6a0584470d0ffa0.webp",980,1306]